LB Pharmaceuticals Inc LBRX
39.71 USD -0.62 (-1.54%)
Nov 4, 2026, 2:01 PM EST
38.75 Day range 41.40
14.32 52-week range 50.16
- YTD
- +78.38%
- 1 year
- +140.65%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 58.00 +46.1% upside
Now 39.71
- Target (low)
- 35.00
- Target (mean)
- 58.00
- Target (high)
- 80.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.60 | -2.21 – -1.07 | -0.61 | -161.8% | 0 | 0.0% | 9 |
| Next quarter | -1.62 | -2.38 – -1.15 | -0.45 | -259.5% | 0 | 0.0% | 9 |
| Current year | -5.61 | -6.85 – -4.63 | -3.13 | -79.3% | 0 | 0.0% | 10 |
| Next year | -5.38 | -7.57 – -4.14 | -5.61 | +4.2% | 0 | 0.0% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Oct 6, 2026 | Guggenheim | Initiated | — | Buy |
| Oct 5, 2026 | Roth Capital | Downgrade | Buy | Neutral |
| Oct 2, 2026 | Needham | Initiated | — | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 12, 2026 | BMO Capital | Maintained | Outperform | Outperform |
| Aug 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 21, 2026 | BMO Capital | Initiated | — | Outperform |
| Jul 7, 2026 | Wolfe Research | Initiated | — | Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Apr 10, 2026 | Craig-Hallum | Initiated | — | Buy |
| Mar 27, 2026 | Stifel | Maintained | Buy | Buy |
| Dec 11, 2025 | Stifel | Maintained | Buy | Buy |
| Oct 6, 2025 | Stifel | Initiated | — | Buy |
| Oct 6, 2025 | Piper Sandler | Initiated | — | Overweight |
| Oct 6, 2025 | Leerink Partners | Initiated | — | Outperform |